“Benefit of using renal sodium-glucose cotransporter inhibitors 2 (iSGLT-2) in patients with type 2 Diabetes Mellitus and Heart Failure”, Acervo Saúde, vol. 12, no. 9, p. e4349, Sep. 2020, doi: 10.25248/reas.e4349.2020.